Maravai LifeSciences Holdings, Inc.

MRVI

US56600D1072

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 24/05/2024 BST			5-day change	1st Jan Change
10.85 ^USD	+0.65%		-4.15%	+65.65%

05-15	Transcript : Maravai LifeSciences Holdings, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 03:35 PM
05-09	UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating	MT

Eric Tardif Plans to Retire as President of Maravai LifeSciences Holdings, Inc., Effective as of June 30, 2021

May 20, 2021 at 09:13 pm

On May 20, 2021, Eric Tardif, President of Maravai LifeSciences Holdings, Inc. announced his plans to retire effective as of June 30, 2021.

Latest news about Maravai LifeSciences Holdings, Inc.

Transcript : Maravai LifeSciences Holdings, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 03:35 PM	05-15
UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating	05-09	MT
Baird Adjusts Price Target on Maravai LifeSciences to $10 From $8, Keeps Outperform Rating	05-09	MT
Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS LLC Reports Q1 Revenue $64.2M, vs. Street Est of $60.5M	05-08	MT
Transcript : Maravai LifeSciences Holdings, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Maravai LifeSciences Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2024	05-08	CI
Maravai LifeSciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego	04-18	MT
Craig-Hallum Initiates Coverage on Maravai LifeSciences With Buy Rating, $15 Price Target	04-10	MT
RBC Raises Price Target on Maravai LifeSciences Holdings to $15 From $14, Keeps Outperform Rating	04-08	MT
Transcript : Maravai LifeSciences Holdings, Inc. Presents at KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum, Mar-19-2024 02:15 PM	03-19
Sector Update: Health Care Stocks Rise in Late Afternoon	02-23	MT
Sector Update: Health Care Stocks Advance Friday Afternoon	02-23	MT
Top Midday Gainers	02-23	MT
Sector Update: Health Care	02-23	MT
Maravai LifeSciences Shares Surge After Price Target Raises, Q4 Beat	02-23	MT
UBS Adjusts Maravai LifeSciences Price Target to $6.50 From $6, Maintains Neutral Rating	02-23	MT
Stifel Trims Price Target on Maravai LifeSciences to $10 From $11, Maintains Buy Rating	02-23	MT
Traders Await Fresh Cues After Nvidia-Fueled Rally as US Equity Futures Inch Higher Pre-Bell	02-23	MT
Sector Update: Health Care Stocks Mixed Premarket Friday	02-23	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday	02-23	MT
RBC Raises Price Target on Maravai LifeSciences Holdings to $14 From $12, Cites 'Clean' Q4, Keeps Outperform Rating	02-23	MT
Top Premarket Gainers	02-23	MT
Maravai LifeSciences' Q4 Adjusted Earnings, Revenue Decline	02-23	MT
Transcript : Maravai LifeSciences Holdings, Inc., Q4 2023 Earnings Call, Feb 22, 2024	02-22

Chart Maravai LifeSciences Holdings, Inc.

Duration

Period

Chart Maravai LifeSciences Holdings, Inc.

More charts

Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities.

Sector

Biotechnology & Medical Research

Calendar

11/06/2024 - Goldman Sachs Global Healthcare Conference - Fireside Chat

More about the company

Income Statement Evolution

More financial data

Ratings for Maravai LifeSciences Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.85 USD

Average target price

10.42 USD

Spread / Average Target

-3.95%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
MARAVAI LIFESCIENCES HOLDINGS, INC.	+65.65%	1.44B
EXACT SCIENCES CORPORATION	-32.63%	9.2B
GUARDANT HEALTH, INC.	-5.66%	3.12B
BGI GENOMICS CO., LTD.	-18.33%	2.05B
VERACYTE, INC.	-24.39%	1.59B
CAREDX, INC	+32.83%	830M
SEEGENE, INC.	-6.77%	720M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-29.80%	507M
CURIOX BIOSYSTEMS CO., LTD	+0.40%	297M
HLB BIOSTEP CO.,LTD.	-17.15%	160M

Bio Diagnostics & Testing

Maravai LifeSciences Holdings, Inc.

Equities

MRVI

US56600D1072

Biotechnology & Medical Research

Eric Tardif Plans to Retire as President of Maravai LifeSciences Holdings, Inc., Effective as of June 30, 2021

Latest news about Maravai LifeSciences Holdings, Inc.

Chart Maravai LifeSciences Holdings, Inc.

Company Profile

Income Statement Evolution

Ratings for Maravai LifeSciences Holdings, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Diagnostics & Testing